AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) Substituted 9a-N-{N'-[4-(sulfonyl)phenylcarbamoyl]} derivatives of ~~9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A~~ 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A and ~~5-O-desosamynil-9-deoxo-9-dihydro--9a-aza-9a-homoerithronolide A~~ 5-O-desosaminyl-9-deoxo-9-dihydro- 9a-aza-9a-homoerythronolide A of the general formula 1,



1

wherein R represents H or cladinosyl moiety, and R^1 represents chloro, amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-5-isoxazolylamino ~~and 5-methyl-3--isoxazolylamino~~ or 5-methyl-3-isoxazolylamino group, ~~and~~ or a pharmacetically acceptable ~~addition salts~~ salt thereof ~~with inorganic or organic acids~~.

2. (currently amended) A substance according to claim 1, characterized in that ~~R1~~ R^1 represents chloro group and R represents cladinosyl moiety.

3. (currently amended) A substance according to claim 1 characterized in that ~~R~~ R^1 represents chloro group, and R represents H.

4. (original) Substance according to claim 1 where R^1 represents amino group, and R represents cladinosyl moiety.

5. (original) A substance according to claim 1, characterized in that R^1 represents phenylamino group, and R represents cladinosyl group.

6. (currently amended) A substance according to claim 1, characterized in that ~~Ri~~ R^1 represents ~~2--pyridylamino~~ 2-pyridylamino group, and R represents cladinosyl group.

7. (currently amended) A substance according to claim 1, characterized in that R^1 represents ~~3,4-dimethyl--5-isoxazolyl~~ 3,4-dimethyl-5-isoxazolyl group, and R represents cladinosyl moiety.

8. (currently amended) A substance according to claim 1, characterized in that R^1 represents ~~5-methyl-3--isoxazolylamino~~ 5-methyl-3-isoxazolylamino group, and R represents cladinosyl group.

9. (original) A substance according to claim 1, characterized in that R^1 represents amino group and R represents H.

10. (original) A substance according to claim 1, characterized in that R^1 represents phenylamino group, and R represents H.

11. (currently amended) A substance according to claim 1, characterized in that R^1 represents ~~2--pyridylamino~~ 2-pyridylamino group, and R represents H.

12. (currently amended) A substance according to claim 1, characterized in that R^1 represents ~~3,4-dimethyl--5-isoxazolylamino~~ 3,4-dimethyl-5-isoxazolylamino group, and R represents H.

13. (currently amended) A substance according to claim 1, characterized in that R^1 represents ~~5-methyl-3- isoxazolylamino~~ 5-methyl-3-isoxazolylamino group and R represents H.

14. (currently amended) A process for the preparation of substituted 9a-N-{N'-[4-(sulfonyl)phenyl carbamoyl]} derivatives of ~~9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A~~ 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A and ~~5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A~~ 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythronolide A of the general formula 1,



1

wherein R^1 represents ~~chloro,~~ amino, phenylamino, 2-pyridylamnio, ~~3,4-dimethyl-5--isoxazolylamino~~ 3,4-dimethyl-5-isoxazolylamino ~~and~~ or 5-methyl-3-isoxazolylamino group and R represents H or cladinosyl group, comprising reacting ~~characterized in that 9a-N-{N'-[4-(chlorosulfonyl)phenyl]- carbamoyl} derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide general formula 1, wherein R^1 represents chloro group and R represent H or cladinosyl group, which can be prepared by reaction of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromicin A~~ 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A or ~~5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A~~ 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythronolide A of general formula 2



2

wherein R represents H or cladinosyl group, with 4-(chlorosulfonyl)phenyl isocyanate formula 3,



3

to form a compound of formula 1 wherein R is H or cladinosyl group and R^1 is chloro; reacting a compound of formula 1 wherein R is H or cladinosyl group and R^1 is chloro ~~are subjected to a reaction~~ with ammonia or amine of general formula 4,

R^2-NH_2

4

~~R2-NH2~~ wherein R^2 represents H, phenyl, 2-pyridyl, 3,4-dimethyl-5-isoxazolyl or 5-methyl-3-isoxazolyl group, in toluene, xylene or some other aprotic solvent, at a temperature 0-110°C ~~and then, if appropriate, to a reaction with inorganic or organic acids~~ to form a compound of formula 1 wherein R is H or cladinosyl and R^1 is amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-5-isozazolylamino or 5-methyl-3-ixozazolylamino.

15. (original) Pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antibacterially effective amount of the substances according to claim 1.

16. cancelled

17. (previously presented) A method for inhibiting bacterial growth in vitro on a surface or in a substance comprising applying to said surface or substance a bactericially effective amount of a compound according to claim 1.

18. (currently amended) The method of claim 17 wherein the surface is selected from the group consisting of a wall, a room, and a medical instrument.

19. (previously presented) The method of claim 17 wherein the substance is selected from the group of wall coatings and wooden coatings.

20. (new) A process for the preparation of substituted 9a-N-{N'-[4-(sulfonyl)phenyl carbamoyl]} derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythronolide A of the general formula 1,



1

wherein R^1 represents chloro and R represents H or cladinosyl group, comprising reacting 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A or 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythronolide A of general formula 2



2

wherein R represents H or cladinosyl group with 4-(chlorosulfonyl)phenyl isocyanate formula 3,



3

to form a compound of formula 1 wherein R is H or cladinosyl and R^1 is chloro.

21. (new) Substituted 9a-N-{N'-[4-(sulfonyl)phenylcarbamoyl]}-derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro- 9a-aza-9a-homoerythronolide A of the general formula 1,



1

wherein R represents H or cladinosyl moiety, and R^1 represents chloro, amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-5-isoxazolylamino or 5-methyl-3-isoxazolylamino group.